Antitumor activity of MDV3100 in a phase I/II study of castration-resistant prostate cancer (CRPC)

被引：0
|
作者：
Scher, H. I.
Beer, T. M.
Higano, C. S.
Taplin, M.
Efstathiou, E.
Anand, A.
Hung, D.
Hirmand, M.
Fleisher, M.
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[2] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[3] Univ Washington, SCCA, Seattle, WA 98195 USA
[4] Dana Farber Canc Inst, Boston, MA 02115 USA
[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[6] Medivation Inc, San Francisco, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5011
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase I/II study of MDV3100 in patients (pts) with progressive castration-resistant prostate cancer (CRPC)
    Scher, H. I.
    Beer, T. M.
    Higano, C. S.
    Danila, D. C.
    Montgomery, B.
    Shelkey, J.
    Hirmand, M.
    Hung, D.
    Sawyers, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [2] CLINICAL STUDY OF MDV3100 IN PROGRESSIVE CASTRATION-RESISTANT PROSTATE CANCER (CRPC)
    Scher, Howard I.
    Beer, Tomasz
    Higano, Celestia
    Efstathiou, Eleni
    Anand, Aseem
    Hirmand, Mohammad
    Hung, David
    Steve, Larson
    Fleisher, Martin
    Sawyers, Charles
    JOURNAL OF UROLOGY, 2009, 181 (04): : 230 - 230
  • [3] Prostate cancer: MDV3100 has antitumor activity in castration-resistant disease
    Payton S.
    Nature Reviews Urology, 2010, 7 (6) : 300 - 300
  • [4] Phase I/II study of the androgen receptor antagonist MDV3100 in castration-resistant prostate cancer
    Scher, Howard I.
    Beer, Thomasz
    Higano, Celestia S.
    Danila, Daniel C.
    Shelkey, Julia
    Hirmand, Mohammed
    Hung, David
    Morris, Michael J.
    Larson, Steve M.
    Sawyers, Charles L.
    CANCER RESEARCH, 2008, 68 (09)
  • [5] Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study
    Scher, Howard I.
    Beer, Tomasz M.
    Higano, Celestia S.
    Anand, Aseem
    Taplin, Mary-Ellen
    Efstathiou, Eleni
    Rathkopf, Dana
    Shelkey, Julia
    Yu, Evan Y.
    Alumkal, Joshi
    Hung, David
    Hirmand, Mohammad
    Seely, Lynn
    Morris, Michael J.
    Danila, Daniel C.
    Humm, John
    Larson, Steve
    Fleisher, Martin
    Sawyers, Charles L.
    LANCET, 2010, 375 (9724): : 1437 - 1446
  • [6] Enhanced antitumor efficacy by combining afatinib with MDV3100 in castration-resistant prostate cancer
    Li, Jianhua
    Wu, Huanxian
    Lv, Shidong
    Quan, Dongling
    Yang, Danni
    Xu, Jiahuan
    Chen, Boyu
    Ou, Baofang
    Wu, Shaoyu
    Wei, Qiang
    PHARMAZIE, 2022, 77 (02): : 59 - 66
  • [7] Re: Antitumour Activity of MDV3100 in Castration-Resistant Prostate Cancer: A Phase 1-2 Study
    Miller, Kurt
    EUROPEAN UROLOGY, 2010, 58 (03) : 464 - 465
  • [8] Antitumour Activity of MDV3100 in Castration-Resistant Prostate Cancer: A Phase 1-2 Study Editorial Comment
    Walsh, Patrick C.
    JOURNAL OF UROLOGY, 2010, 184 (06): : 2330 - 2330
  • [9] Phase I-II study of MDV3100 in castration resistant prostate cancer. The Prostate Cancer Clinical Trials consortium
    Scher, H.
    Beer, T.
    Higano, C.
    Logothetis, C.
    Shelkey, J.
    Hung, D.
    Hirmand, M.
    Larson, S.
    Fleisher, M.
    Sawyers, C.
    EJC SUPPLEMENTS, 2008, 6 (12): : 51 - 52
  • [10] Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone
    Bianchini, D.
    Lorente, D.
    Rodriguez-Vida, A.
    Omlin, A.
    Pezaro, C.
    Ferraldeschi, R.
    Zivi, A.
    Attard, G.
    Chowdhury, S.
    de Bono, J. S.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (01) : 78 - 84
12345